InnoCare Pharma News

[Brokerage Focus] CMB International maintains a Buy rating on INNOCARE (09969) and stated that the self-immune pipeline will further drive business growth.

Jingu Financial NewsJan 24 13:25

INNOCARE PHARMA(9969.HK):AUTOIMMUNE THERAPIES AS A SECOND GROWTH ENGINE

Jan 24 08:52

Nuochengjianhua (688428) Company Brief Review Report: Rapid Dosage of Obutinib Has Broad Prospects for Self-Exemption

CITIC SecuritiesJan 23 20:17

Nuochengjianhua (688428): Obutinib doses can be expected to prevent tumors and go hand in hand

SinolinkJan 23 00:00

Nuocheng Jianhua (688428): Accelerating R&D in the field of high-speed release of hematoma products and self-exemption

China International Capital CorporationJan 17 18:22

[Brokerage Focus] Guoyuan International gives INNOCARE (09969) a "Buy" rating, citing scientific innovation as a driver for the company's development.

Jinwu Financial NewsJan 3 11:30

Nuochengjianhua-B (9969.HK): Innovation drives the company's development to comprehensively lay out the field of self-defense

Guoyuan InternationalDec 31, 2024 00:00

Nuocheng Jianhua (9969.HK): Equity incentives highlight confidence in development and enter a new era of rapid 2.0 development

Southwest SecuritiesNov 27, 2024 00:00

Nuocheng Jianhua (688428): Oncology Immunity Two Blossoming Companies have entered a period of rapid growth

caitongNov 18, 2024 10:26

Nuocheng Jianhua (9969.HK): Revenue exceeds expectations and the self-exemption pipeline progresses smoothly

gtjaNov 13, 2024 07:42

INNOCARE PHARMA LIMITED(09969.HK):STRONG SALES PERFORMANCE IN 3Q24

Nov 12, 2024 19:27

Nuochengjianhua (688428): Sales of obutinib slightly exceeded expectations, and the annual sales guide was further raised to 45% year-on-year growth

Ping An Bank InternationalNov 12, 2024 00:00

Jefferies Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)

TipRanksOct 27, 2024 20:17

Nuochengjianhua (688428) Company's First Coverage Report: Global Hematoma Leaders Open a Second Growth Curve

Open Source SecuritiesOct 25, 2024 00:00

UBS Group: Raises Innocare's target price to 8.6 Hong Kong dollars, maintains a "buy" rating.

Gelonghui FinanceOct 14, 2024 15:45

UBS Group: Maintains a "buy" rating on Innocare (09969) with a target price raised to 8.6 Hong Kong dollars.

Zhitong FinanceOct 14, 2024 15:40

Nuochengjianhua (688428): A complete breakthrough in the variant TYK2 inhibitor with excellent psoriatic phase 2 data immunity pipeline

The Pacific SecuritiesOct 14, 2024 00:00

Research reports dig gold丨gtja: innocare ICP-488 domestic progress leading, chronic disease pipeline accelerated advancement.

Gelonghui FinanceOct 12, 2024 15:02

Nuochengjianhua (9969.HK): 488 excellent clinical data, accelerated progress of the chronic disease pipeline

gtjaOct 12, 2024 07:51

Nuocheng Jianhua (9969.HK): Phase MSIII received FDA approval to open overseas space

Sep 9, 2024 13:46